Status: Recruiting
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
This is a Phase II study of the combination of All-Trans Retinonic Acid (ATRA) and PD-1 inhibition (Retifanlimab) in patient with recurrent IDH-mutant glioma. The Sponsor-Investigator hypothesizes that the proposed regimen will be safe and stimulate a robust anti-tumor immune response.
Participants needed: 55
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Stephen Bagley, MD, MSCEUpdated: Feb 20, 2026Locations: 1
Eligibility criteria
Prior histopathologically proven diagnosis of astrocytoma (grade 2-4) or oligode... [+41]
Contrast-enhancing tumor in brainstem or spinal cord (subjects do not need spina... [+28]